This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
by Zacks Equity Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study
by Zacks Equity Research
Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.
AstraZeneca's (AZN) Fasenra sBLA for Nasal Polyps Gets CRL
by Zacks Equity Research
The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical
AstraZeneca (AZN) Stock Up 27% in a Year: What Lies Ahead?
by Zacks Equity Research
AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.
Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study
by Zacks Equity Research
Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.
AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Valneva (VALN) Completes Phase III Chikungunya Vaccine Study
by Zacks Equity Research
Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.
Merck (MRK) Outperforms Industry, What's in Store for 2022?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.
AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.
Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals
by Kinjel Shah
Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Pharma Stock Roundup: EU Approval to PFE, AZN Products, FDA Nod to LLY New COVID Drug
by Kinjel Shah
FDA grants EUA to Eli Lilly's (LLY) new COVID antibody-drug, bebtelovimab. AstraZeneca's (AZN) Saphnelo and Pfizer's (PFE) Ngenla (somatrogon) and Apexxnar vaccine get approval in Europe
AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod
by Zacks Equity Research
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
by Kinjel Shah
Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.
Company News for Feb 11, 2022
by Zacks Equity Research
Companies in The News Are: KO,AZN,K,WEX
AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance
Why AstraZeneca (AZN) Might Surprise This Earnings Season
by Zacks Equity Research
AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.